Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab (vunakizumab) dose reduction strategies in active ankylosing spondylitis
ChiCTR2500104867Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Kunming Medical University
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of secukinumab in ankylosing spondylitis (AS) (3 arms), sponsored by First Affiliated Hospital of Kunming Medical University. Primary endpoints: ASAS40 response at 12 weeks and Sustained clinical remission over 52 weeks. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on ChiCTR2500104867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104867.